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Abstract
Major genetic factors for age-related macular degeneration (AMD) have recently been identified as susceptibility risk factors,
including variants in the CFH gene and the ARMS2 LOC387715/HTRA1locus. Our purpose was to perform a case-control study
in two populations among individuals who did not carry risk variants for CFHY402H and LOC387715 A69S (ARMS2), called
‘‘study’’ individuals, in order to identify new genetic risk factors. Based on a candidate gene approach, we analyzed SNP
rs5888 of the SCARB1 gene, coding for SRBI, which is involved in the lipid and lutein pathways. This study was conducted in
a French series of 1241 AMD patients and 297 controls, and in a North American series of 1257 patients with advanced AMD
and 1732 controls. Among these individuals, we identified 61 French patients, 77 French controls, 85 North American
patients and 338 North American controls who did not carry the CFH nor ARMS2 polymorphisms. An association between
AMD and the SCARB1 gene was seen among the study subjects. The genotypic distribution of the rs5888 polymorphism was
significantly different between cases and controls in the French population (p,0.006). Heterozygosity at the rs5888 SNP
increased risk of AMD compared to the CC genotypes in the French study population (odds ratio (OR)=3.5, CI95%: 1.4–8.9,
p,0.01) and after pooling the 2 populations (OR=2.9, 95% CI: 1.6–5.3, p,0.002). Subgroup analysis in exudative forms of
AMD revealed a pooled OR of 3.6 for individuals heterozygous for rs5888 (95% CI: 1.7–7.6, p,0.0015). These results suggest
the possible contribution of SCARB1, a new genetic factor in AMD, and implicate a role for cholesterol and antioxidant
micronutrient (lutein and vitamin E) metabolism in AMD.
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Introduction
Age-related macular degeneration (AMD) is the most common
cause of irreversible vision loss in the elderly population in Europe
and United States [1,2]. Identification of risk factors is of major
importance for the understanding of the origins of the disorder and
for establishing strategies to prevent AMD. Risk factors for AMD
are both environmental [3–9] and genetic [10–14]. Over the past
few years, several single nucleotide polymorphisms (SNPs) have
been associated with AMD, including variants in the CFH and
ARMS2 genes [15–26,64]. The association between these polymor-
phisms and AMD risk suggests a pathway of inflammation and
oxidation in AMD. Besides these pathways, several lines of evidence
suggest a strong role of antioxidant micronutrients (xanthophylls,
vitamin E and vitamin C) and lipids in AMD [8,27–33].
Our purpose was to assess candidate genes and polymorphisms
involved in the lipid pathway among individuals harboring non-risk
alleles for CFH and ARMS2. The SCARB1 gene which encodes
SRB1, a multiligand cell surface receptor, is known to mediate
selective cholesterol uptake, and cholesterol efflux [34–37], and was
regarded as an attractive candidate gene. Furthermore, recent
studies have shown that SCARB1 is also involved in uptake of
vitamin E and lutein giving further support to a possible role of
SCARB1 in AMD [38,39]. In fact, the xanthophyll, lutein, is
recovered at high concentration in the human macula lutea and has
been associated with the risk of AMD, and vitamin E, the main
lipophilic antioxidant, is suspected to prevent oxidation of
polyunsaturated fatty acids recovered at high concentrations in
the human retina [40–42]. Several studies have suggested that
SCARB1 genotypes for the rs5888 synonymous SNP may play a role
in cholesterol homeostasis and is associated with cardiovascular
diseases [43–48]. Herein, we report a possible association between
the SCARB1 rs5888 SNP and AMD in a subgroup of French and
North American AMD patients in a case-control study.
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TheFrenchcohortconsistedof1241cases(92%exudativeAMD,
5.2% geographic atrophy, 2.8% early or intermediate AMD) and
297 controls. The mean6SD age at AMD diagnosis was 78.867.5
years. The North American cohort consisted of 1732 advanced
AMD cases (72.4% exudative AMD, 27.6% geographic atrophy)
and 1257 controls. All subjects were Caucasian. The mean6SD age
at AMD diagnosis was 80.366.5 years (Table 1).
The genotype distributions of the rs1061170, rs10490924 and
rs5888 SNPs within the CFH, ARMS2 and SCARB1 genes,
respectively, are shown in Table 2. The genotypic distributions
of the CFH Y402H and ARMS2 SNPs were significantly different
between cases and controls in both the French and North
American series (p,0.0001 for both groups). For rs5888
genotypes, regardless of CFH or ARMS2 genotypes, no significant
association was found in the entire French population of AMD
patients (Table 2). However, the distribution of the SCARB1
rs5888 genotype was significantly different in the North American
AMD population compared to controls (p,0.004): CT heterozy-
gotes were at increased risk of AMD compared to CC subjects
(adjusted ORCT vs CC=1.4, 95%CI 1.0–1.8), TT did not
significantly differ from CC (adjusted OR=1.2 CI95% 0.9–
1.7).Similar results were obtained after pooling the French and the
North American population: adjusted ORCT vs CC=1.3, 95%CI:
1.0–1.7) and adjusted ORTT vs CC=1.2, 95%CI 0.9–1.7. Odds
Ratio were adjusted for non genetic confounders: age, gender and
smoking status.
Characteristics of subjects carrying no risk alleles at the CFH
and ARMS2 loci are shown in Table 3 (and Table S1). In the
French population, genotypic distribution of the SCARB1
polymorphism was significantly (p,0.01) different between cases
and controls: CT heterozygotes compared to CC subjects were at
increased risk of AMD. (adjusted OR 3.5, 95%CI1.4–8.9). In the
North American population, we observed a suggested increased
risk of AMD associated with heterozygocity at the rs5888 (global
test p,0.09): ORCT vs CC=2.5; 95%CI 1.1–5.7. Similar results
were obtained when pooling French and North American
populations (global test, p,0.002), in that CT individuals were
at increased risk of AMD compared to CC genotypes: adjusted
OR=2.9; 95%CI1.6–5.3 while TT subjects did not significantly
differ from CC subjects (Table 4).
In exudative AMD subgroups (Cases: n=105, 55 French and
50 American; controls: n=415, 77 French and 338 American),
Table 1. Non-genetic characteristics of the entire French and North American populations.
French population USA population
Controls Cases Controls Cases p
N 297 1241 1257 1732
Sex, men, n(%) 110 (39.4%) 415 (33.4%) #0.06 543 (43.2%) 750 (43.3%) ,0.96
Age, m (sd)* 69.2 (7.4) 78.8 (7.5) ,0.0001 75.0 (5.5) 80.3 (6.5) ,0.0001
Smoking
Current, n(%) 89 (30.1%) 106 (8.6%) ,0.0001 27 (4.6%) 98 (7.9%) ,0.005
Never, n(%) 163 (55.1%) 770 (62.1%) 251 (42.9%) 455 (36.7%)
Past, n(%) 44 (14.8%) 364 (29.3%) 307 (52.5%) 686 (55.4%)
doi:10.1371/journal.pone.0007341.t001
Table 2. Genotype distributions among the entire French and North American populations.
French population USA population
Controls Cases Controls Cases p
N 297 1241 1257 1732
CFHY402H (rs1061170)
CC 35 (11.8%) 356 (28.7%) ,0.0001 154 (12.3%) 654 (37.8%) ,0.0001
CT 146 (49.2%) 628 (50.6%) 562 (44.7%) 815 (47.1%)
TT 116 (39.0%) 257 (20.7%) 541 (43.0%) 263 (15.2%)
ARMS2 (rs10490924)
GG 195 (65.7%) 397 (32.0%) ,0.0001 799 (63.6%) 542 (31.3%) ,0.0001
GT 92 (31.0%) 577 (46.5%) 416 (33.1%) 814 (47.0%)
TT 10 (3.4%) 267 (21.5%) 42 (3.3%) 376 (21.7%)
SRB1 (rs5888)
CC 79 (26.6%) 317 (25.5%) ,0.89 376 (29.9%) 433 (25.0%) ,0.004
CT 151 (50.8%) 629 (50.7%) 585 (46.5%) 903 (52.1%)
TT 67 (22.6%) 295 (24.8%) 296 (23.6%) 396 (22.9%)
P values: global chi
2 test with 2 degrees of freedom for comparison of genotype distribution between cases and controls.
doi:10.1371/journal.pone.0007341.t002
SCARB1 Gene and AMD
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individuals was: OR=3.6, 95%CI: 1.7–7.6, p,0.0015.
Discussion
Here we report for the first time a possible association between a
polymorphism in the SCARB1 gene and AMD, in two distinctly
different Caucasian populations.
AMD is a multifactorial disorder including both environmental
and genetic factors. Among the long list of genes potentially
involved in AMD [49], two major genes have been recently
associated to AMD: CFH and ARMS2 [15–26,64]. Because, double
homozygosity for the CFH and ARMS2 risk alleles account for more
than 50% in the pathology of AMD [50,51], we hypothesized that
candidate gene screening in a subgroup of AMD patients and
controls homozygous for CFH and ARMS2 wild-type alleles may
help in identifying novel and independent genetic risk factors. One
limit of our study is the sample size of our populations without the
CFH and/or the ARMS2 at-risk alleles. Only 61/1241 (4.9%) of
AMD French patients and 85/1732 (4.9%) of American AMD did
not carry one of these at-risk alleles. Thus, it requires large series of
patients in order to assure that somepatients without the CFHand/
or the ARMS2 at-risk alleles are present in the final sample.
Heterozygosity for the rs5888 SNP of the SCARB1 gene (CT) may
be associated with an increased risk of AMD in the French and North
American populations, respectively. Nevertheless, our findings have to
be interpreted very cautiously. Heterozygosity was found significantly
associated to AMD in wild-type individuals for CFH and ARMS2 in
the French group (p,0.01), and in the same direction but not
significant in the North American population (p,0.09). Heterozygos-
ity at the rs5888 was also found to be significantly associated with
A M Dw h e na l lN o r t hA m e r i c a ni n d i v i d u a l s ,r e g a r d l e s so ft h e i r
genotypes at the CFH and ARMS2 loci, were considered (p,0.004),
but not in the French population. This discrepancy might be
explained by the low number of French controls, compared to the
North-American sample. However the number of French AMD
patients and controls (respectively 1241 and 297) was evaluated in
order to obtain similar number of AMD patients and controls in wild-
types groups with no risk alleles for CFH and ARMS2 (respectively 61
and 77). An association between rs5888 of SCARB1 and the exudative
type of AMD was observed (OR: 3.6, 95%CI: 1.7–7.6; p,0015). We
enrolled a large number of exudative forms of AMD because patients
with neovascular AMD are most often referred to our specialized
retina departments than atrophic forms of AMD.
SCARB1 gene is located in 12q24.31, in a region of interest
pointed by linkage analysis [52,53]. SCARB1 gene encodes a
multiligand cell surface receptor that mediates selective cholesterol
uptake, and cholesterol efflux [34–37]. Reverse cholesterol
transport, is a major pathway for the clearance of excess
cholesterol from the body. Several studies have reported that the
SCARB1 rs5888 SNP is associated with the development of
coronary heart disease [44], and lipid profile [45–48]. Indeed,
epidemiological studies in Caucasian populations have shown that
the rs5888 is associated with increased HDL cholesterol and lower
LDL cholesterol, and rs5888 has been reported to be associated
with a greater risk of developing coronary heart disease in males
[44]. Because AMD and cardiovascular diseases share common
pathways [54–56], we decided to analyze genes involved in lipid
homeostasis. Furthermore, it is known that SCARB1 is also
expressed in the retinal pigment epithelium [57], and could
interact with APOE, another gene which some groups but not all
have reported to be involved in AMD [58,59]. Besides the
pathway of lipids, SCARB1 is also involved in the metabolism of
lutein and vitamin E [60]. Lutein, obtained from foods, is a
member of the carotenoid family, more specifically the xantho-
phyll family. Lutein protects the photoreceptors against light-
Table 3. Non-genetic characteristics of the French and North American populations with no risk alleles for CFH and ARMS2.
French population USA population
Controls Cases Controls Cases p
N 77 61 338 85
Sex, men, n(%) 23 (31.9%) 16 (26.2%) ,0.48 144 (42.6%) 39 (45.9%) ,0.59
Age, m (sd)* 70.3 (7.2) 77.9 (9.8) ,0.0001 74.8 (5.6) 79.0 (8.0) ,0.0001
Smoking
Current, n(%) 19 (24.7%) 10 (16.4%) ,0.50 8 (5.0%) 8(14.3%) ,0.062*
Never, n(%) 46 (59.7%) 41 (67.2%) 72 (45.0%) 20 (35.7%)
Past, n(%) 12 (15.6%) 10 (16.4%) 80 (50.0%) 28 (50.0%)
doi:10.1371/journal.pone.0007341.t003
Table 4. Adjusted Odds ratio for rs5888 of SCARB1 gene in
patients with no risk alleles for CFH and ARMS2.
CC CT TT
OR [CI95%] OR [CI95%] P*
France 1 (ref) 3.5 [1.4–8.9] 1.0 [0.3–3.2] ,0.01
USA 1 (ref) 2.5 [1.1–5.7] 2.0 [0.8–5.2) ,0.09
Pooled 1 (ref) 2.9 [1.6–5.3] 1.6 [0.8–3.3] ,0.002
Gender-Pooled
Men 1 (ref) 4.3 [1.5–11.9] 1.8 [0.5–6.3] ,0.02
Women 1 (ref) 2.5 [1.2–5.5] 1.7 [0.7–4.3] ,0.07
Exudative forms
France 1 (ref) 3.6 [1.3–10.0] 1.1 [0.3–4.0] ,0.02
USA 1 (ref) 3.5 [1.1–10.5] 2.2 [0.6–8.0] ,0.09
Pooled 1 (ref) 3.6 [1.7–7.6] 1.6 [0.7–4.0] ,0.0015
Adjustment for non genetic confounders: age, sex, and cigarette smoking.
For table 4, OR are estimated by genotype (CT vs CC and TT vs CT) but the p
values are global p values (with 2 degrees of freedom) for estimates a global
effect of genotype (is at least one of the genotypes (CT or TT) significantly
associated with increased rik of AMD).
*Interaction with center; p,0.29, interaction with sex (in pooled population),
p,0.48.
Sample size: France: 61 cases and 72 controls – USA: 56 cases and 160 controls.
doi:10.1371/journal.pone.0007341.t004
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based on diet questionnaires or serum levels of lutein revealed that
high levels of lutein are associated with a decreased risk of AMD
[8,61]. Vitamin E acts as an antioxidant, protecting the retina
against oxidative stress, with possible preventive and therapeutic
effects [33,40,41]. SCARB1 is involved in the metabolism of three
key molecules involved in the etiology of AMD: cholesterol, lutein
and vitamin E, all supported by fundamental and epidemiological
studies. For these reasons based on gene function and gene
location, we considered SCARB1 as a good candidate gene for
AMD. The greater risk of AMD found in CT individuals
heterozygous at rs5888 has already been reported in peripheral
arterial disease [43]. The rs5888 SNP is a coding-synonymous
polymorphism (A350A). This polymorphism may nevertheless be
in linkage disequilibrium with a functional sequence change as
recently demonstrated with the identification of the rs10490924
polymorphism in the ARMS2 gene which results in instability of
the transcript [62]. To evaluate this hypothesis, we sequenced the
13 SCARB1 exons (in 8 patients: 3 patients TT, 2 patients CC and
3 patients CT) and 200 kb of the 59UTR in 92 wild-type
individuals patients and controls, but we did not found any
anomalies in the gene sequence, neither insertions or deletions
such as the one described in the SCARB1 promotor [63]. The
relatively small sample size in some of the subgroup analyses could
also explain some of the findings. On the other hand, it is also
possible that the rs5888 polymorphism has a functional effect
through a mechanism involving splicing regulatory system. From
this point of view it is worth noting that it has been shown that
SCARB1 mRNA expression is significantly decreased in heterozy-
gous individuals compared to homozygous CC or TT [43]. ‘‘A
dominant-negative effect can be suggested.’’ Further studies will
hopefully bring insights into this intriguing question.
In conclusion, our results suggest that the SCARB1 polymor-
phism is associated with AMD. This genetic finding is consistent
with basic and epidemiological studies underlying the role of
cholesterol, lutein and vitamin E in AMD. Additional studies
including correlations with serum analysis and larger samples sizes
are needed to confirm this finding.
Methods
French Populations
Patients. Written informed consent was obtained, as required
by the French bioethical legislation and local ethic committee
(CCPPRB Henri Mondor), in agreement with the Declaration of
Helsinki for research involving human subjects.
A total of 1241 French AMD patients were recruited in 4
French Ophthalmologic Centres, at the Ophthalmology Eye
Clinic of Cre ´teil in collaboration with the Pellegrin Hospital, the
Quinze-Vingts Hospital and the Centre of Imaging and Laser of
Paris, between November 2005 and July 2007. Inclusion criteria of
the AMD patients were (1) women or men aged 55 or older, and
(2) with exudative AMD, atrophic AMD or with early or
intermediate AMD (also called Aged-Related Maculopathy) in at
least one eye. Exclusion criteria were presence of other retinal
disease (e.g. diabetic retinopathy, high myopia, or macular
dystrophies). Patients underwent a complete ophthalmologic
examination including best corrected visual acuity measurement,
fundus examination, and retinal photographs. Fluorescein angi-
ography (Topcon 50IA camera, Tokyo, Japan)- and if needed
indocyanine green angiography (HRA, Heidelberg, Germany)-
and Optical Coherence Tomography (Carl Zeiss Meditec, Inc)
were performed. A questionnaire about medical history and
smoking was completed.
Controls. A total of 297 French women or men over 55 years
with a normal fundus examination and a normal aspect of fundus
photography were also recruited at the Ophtalmology Eye Clinic
of Cre ´teil between 2002 and 2008. Information about their
medical history including smoking, was obtained.
Genotyping Methods. Genomic DNA was extracted from
10 mL blood leukocytes using the IllustraH kit according to the
manufacturer protocol (GE Healthcare). The SCARB1 rs5888 CFH
Y402H and ARMS2 rs10490924 SNPs were genoyped by quantitative
PCR allelic discrimination using reagents and conditions from
Custom Taqman SNP Genotyping Assays (Applera Corp., France),
using ABI 7900HT (Applied Biosystems) [24].
North American Populations
Patients. Subjects and methods of diagnosis and enrollment
have been previously described [64]. All patients had advanced
age-related macular degeneration, either exudative or geographic
atrophy, and diagnosis was based on ocular examination and
fundus photography. They were all Caucasian and unrelated
(Table 1).
Controls. Caucasian individuals without AMD who were
unrelated to the cases and to other controls were enrolled. Absence
of AMD was based on ocular examination and grading of fundus
photographs [64] (Table 1). All cases and controls signed a written
informed consent form.
Genotyping Methods. DNA samples were evaluated for the
rs5888 SNP using either the Affymetrix 6.0 platform as part of our
genome-wide association study (under review) or the Sequenom
platform. Genotyping was performed at the Broad Institute in
Cambridge, MA, USA.
Statistical Analysis. Hardy-Weinberg assumption was
assessed by the standard method comparing the observed
numbers of subjects in different genotype categories with the
expected number under Hardy-Weinberg equilibrium for the
estimated allele frequency, and testing with a Pearson goodness-of-
fit statistic with the x
2 with 1 degree of freedom.
x2 test was used to compare categorical allelic and genotype
distributions between cases and controls (table 1). General linear
models were used to compare means between cases and controls.
Logistic regression models were used to estimated odds ratio (OR)
with 95% confidence interval (95%CI) for AMD risk. OR’s were
adjusted for age, gender and smoking status. Significance levels
were set at p,0.05. Analyses were performed with the SAS
software release 9.01 (SAS Institute INC, Cary, NC).
Homogeneity between the 2 populations was tested by
introduction of interaction terms with study center in the models
(1rst test), by Breslow-day Test for homogeneity of the odds ratio
(2nd test) and by I
2 (= % of heterogeneity). I
2 has been estimated
by the software Review Manager 5. I
2 and Breslow-Day test have
been made without adjustment.
Supporting Information
Table S1 Genotype distribution for SCARB1 (rs5888) in the
French and North American individuals with no risk alleles for
CFH (rs1061170) and ARMS2 (rs10490924). P values: global chi
2
test with 2 degrees of freedom for comparison of genotype
distribution between cases and controls.
Found at: doi:10.1371/journal.pone.0007341.s001 (0.03 MB
DOC)
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